ALLMedicine™ Myelofibrosis Center

May 20th, 2022 - The objective of study IOA-244-101 is to determine whether IOA-244 is safe and tolerable in cancer patients (Part A). In addition, the study will assess whether IOA-244 can increase the anti-tumour immune response in patients both as monotherapy a...

May 19th, 2022 - Permitted Concomitant Medications and Procedures Subjects are receiving a JAK2 inhibitor for the treatment of MPN-associated MF that is approved in the country where the study is being conducted. JAK2 inhibitors are to be used according to their r...

May 19th, 2022 - The purpose of this study is to investigate the safety, pharmacokinetics and preliminary efficacy of combinations treatment of ruxolitinib with 5 novel compounds: siremadlin, crizanlizumab, sabatolimab, LTT462 and NIS793 in myelofibrosis (MF) subj...

May 19th, 2022 - Prospective participants must be on stable doses of ruxolitinib ranging from 5 mg BID to 25 mg BID and will have been on that dose for at least the last 8 weeks prior to Day 1. At least 3 months duration of prior ruxolitinib is required. Participa...

May 19th, 2022 - The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of INCB057643 as monotherapy or combination with ruxolitinib for participants with myelofibrosis and other myeloid neoplasms.

Feb 23rd, 2020 - A physician survey on the application of the British Society for Haematology guidelines for the diagnosis and management of myelofibrosis in the UK.|2020|Harrison CN,Mead AJ,Drummond MW,Chiu G,Bains R,|diagnosis,therapy,

Oct 7th, 2017 - Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thromboh...

Dec 14th, 2016 - Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are a group of heterogeneous disorders of the hematopoietic system collectively known as Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs). The diagn...

Jun 2nd, 2012 - The guideline group regarding the diagnosis and management of myelofibrosis was selected to be representative of UK-based medical experts, together with a contribution from a single expert from the USA. MEDLINE and EMBASE were searched systematica...

May 20th, 2022 - The objective of study IOA-244-101 is to determine whether IOA-244 is safe and tolerable in cancer patients (Part A). In addition, the study will assess whether IOA-244 can increase the anti-tumour immune response in patients both as monotherapy a...

May 19th, 2022 - Permitted Concomitant Medications and Procedures Subjects are receiving a JAK2 inhibitor for the treatment of MPN-associated MF that is approved in the country where the study is being conducted. JAK2 inhibitors are to be used according to their r...

May 19th, 2022 - The purpose of this study is to investigate the safety, pharmacokinetics and preliminary efficacy of combinations treatment of ruxolitinib with 5 novel compounds: siremadlin, crizanlizumab, sabatolimab, LTT462 and NIS793 in myelofibrosis (MF) subj...

May 19th, 2022 - Prospective participants must be on stable doses of ruxolitinib ranging from 5 mg BID to 25 mg BID and will have been on that dose for at least the last 8 weeks prior to Day 1. At least 3 months duration of prior ruxolitinib is required. Participa...

May 19th, 2022 - The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of INCB057643 as monotherapy or combination with ruxolitinib for participants with myelofibrosis and other myeloid neoplasms.

May 4th, 2022 - Ruben A. Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses the future of JAK inhibitor therapy in myelofibrosis. The addition of more treatment options for myelofibrosis has been a benefit ...

May 3rd, 2022 - Srdan Verstovsek, MD, PhD, professor, director, Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms, chief, Section for Myeloproliferative Neoplasms, Department of Leukemia, The University of Texas MD Anderson Cancer Center,...

May 2nd, 2022 - Srdan Verstovsek, MD, PhD, professor, director, Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms, chief, Section for Myeloproliferative Neoplasms, Department of Leukemia, The University of Texas MD Anderson Cancer Center,...

Apr 25th, 2022 - The use of ruxolitinib (Jakafi) following an allogeneic hematopoietic cell transplantation (HCT) was associated with the prevention of serious graft-versus-host disease (GHVD), according to interim data from 2 ongoing phase 2 trials (NCT03286530 a...

Apr 5th, 2022 - Jacqueline S. Garcia, MD, assistant professor of medicine, Harvard Medical School, physician, Dana-Farber Cancer Institute, discusses the results of the phase 2 REFINE trial (NCT03222609) in patients with myelofibrosis. Patients eligible to par...